Gilead Complera Launch Imminent Following FDA Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Antiretroviral combines Gilead's Truvada with J&J's Edurant for HIV, and is intended as a replacement to the existing triple combination Atripla.